Offering SPR-BLI Services - Proteins provided for free! Here come GMP Grade Cytokines!Free Sample is available!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
Trop2 ADC -01 | IND | Solid Tumor | Non-small cell lung cancer,Pancreatic cancer |
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
Trop2 ADC | Bioconjugates | Oncology/Cancer | Gastric cancer,Pancreatic cancer | IND | Global |
Immobilized Mouse Monoclonal Antibody Against Human TROP-2 Protein,Mouse IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus TROP-2 Protein, His,Avitag (Cat. No. TR2-C82E3) with a linear range of 5-39 ng/mL (QC tested).
The purity of Cynomolgus TROP-2 Protein, His Tag (Cat. No. TR2-C52H5) is more than 90% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Sacituzumab govitecan | IMMU0132; GS-0132; IMMU-0132; IMMU-132; TROP-2-SN-38 | Approved | Immunomedics Inc, Gilead Sciences Inc | Trodelvy, 拓达维, TRODELVY | United States | Triple Negative Breast Neoplasms | Immunomedics Inc | 2020-04-22 | Small Cell Lung Carcinoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Metastatic breast cancer; Brain metastases; Endometrial Neoplasms; Bile Duct Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Klatskin Tumor; Urinary Bladder Neoplasms; Carcinoma, Ovarian Epithelial; Solid tumours; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Salivary Gland Neoplasms; Glioblastoma; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Liver Failure; Ovarian Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
FDA018 Antibody Drug Conjugate | FDA-018-ADC; FDA018-ADC | Phase 2 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Neoplasm Metastasis | Details |
BL-M02D1 | Phase 2 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
MT-302 | MT-302 | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
重组人源化抗Trop2单抗-SN38偶联物 | ESG-401; STI-3258 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd, Tot Biopharm Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
HS-20105 | HS-20105; HS20105 | Phase 2 Clinical | Hansoh BioMedical R&D Company | Solid tumours | Details |
BIO-106 | BIO-106 | Phase 2 Clinical | Hangzhou Baikai Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
DB-1305 | DB1305; DB-1305 | Phase 2 Clinical | Duality Biologics Co Ltd | Solid tumours | Details |
OBI-992 | OBI-992 | Phase 2 Clinical | Obi Pharma Usa Inc | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
9MW-2921 | 9MW2921; 9MW-2921 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours | Details |
MHB036C | MHB-036C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
DAC-002 | JS-108; DAC-002 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma | Details |
LCB-84 | LCB-84 | Phase 2 Clinical | Legochem Biosciences Inc | Solid tumours | Details |
SHR-A1921 | SHR-A1921; SHRA1921 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Solid tumours; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms | Details |
BAT-8008 | BAT8008; BAT-8008 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
Anti TROP2 antibody drug conjugate ADC(Fudan University) | Phase 2 Clinical | Fudan University | Triple Negative Breast Neoplasms | Details | |
Datopotamab deruxtecan | Dato-DXd; DS-1062a; DS-1062 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Ovarian Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.